Annals of Pharmacotherapy 2016-Apr
Comment: Management of De Novo Chronic Myelogenous Leukemia and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation Tyrosine Kinase Inhibitor Dasatinib.
Solo gli utenti registrati possono tradurre articoli
Entra registrati
Il collegamento viene salvato negli appunti